甲状腺功能亢进患者应用甲亢平消方联合甲巯咪唑治疗的临床效果研究  

Clinical effects of Jiakang Pingxiao prescription combined with methiimidazole on hyperthyroidism

作　　者：徐萌[1] 任单阳 吴燕[1] 包含 尘丹 Xu Meng;Ren Danyang;Wu Yan;Bao Han;Chen Dan(Department of Endocrinology,Shanxian Central Hospital,Heze 274300,Shandong Province,China)

机构地区：[1]单县中心医院内分泌科,菏泽274300

出　　处：《中国基层医药》2023年第7期996-999,共4页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的探讨甲亢平消方联合甲巯咪唑治疗甲状腺功能亢进症(甲亢)的临床效果。方法选取单县中心医院2018年2月至2021年1月收治的甲亢患者100例为研究对象,采用随机数字表法分为研究组与对照组,每组50例。对照组予以甲巯咪唑治疗,研究组在此基础上予以甲亢平消方治疗,比较两组患者甲状腺功能、血清骨钙素(OCN)、β胶联降解产物(β-CTx)、超敏C反应蛋白(hs-CRP)、白细胞介素6(IL-6)水平。结果治疗后,研究组患者血清促甲状腺激素(TSH)[(3.10±1.36)mU/L]、游离三碘甲状腺原氨酸(FT3)[(5.76±1.25)pmol/L]、游离甲状腺素(FT4)[(15.22±1.95)pmol/L]均显著低于对照组[(4.88±1.47)mU/L、(7.13±1.32)pmol/L、(19.07±2.02)pmol/L](t=5.27、4.71、6.29,均P < 0.05);研究组血清OCN[(17.36±2.62)μg/L]、β-CTx[(0.32±0.04)μg/L]、hs-CRP[(4.07±0.86)mg/L]、IL-6[(1.38±0.21)pg/L]显著低于对照组(26.05±2.88)μg/L、(0.51±0.09)μg/L、(6.23±0.91)mg/L、(1.89±0.28)pg/L](t=12.37、10.40、7.39、8.57,均P < 0.05)。研究组不良反应发生率[6.00%(3/50)]显著低于对照组[12.00%(3/50)](χ^(2)=14.78,P < 0.05)。结论甲亢平消方联合甲巯咪唑治疗可有效减轻甲亢患者的炎症反应,抑制血清OCN、β-CTx表达,改善甲状腺功能,其治疗方法科学合理符合临床,且效果良好,值得推广。Objective To investigate the clinical effects of Jiakang Pingxiao prescription combined with methiimidazole on hyperthyroidism.Methods A total of 100 patients with hyperthyroidism admitted to Shanxian Central Hospital from February 2018 to January 2021 were included in this study.They were randomly divided into a study group and a control group,with 50 patients in each group.The control group was treated with methiimidazole,and the study group was treated with Jiakang Pingxiao prescription combined with methiimidazole.Thyroid function,serum levels of osteocalcin(OCN),β-CTx,hypersensitive C-reactive protein,and interleukin-6(IL-6)were compared between the two groups.Results After treatment,serum levels of thyroid stimulating hormone(TSH),free triiodothyronine(FT3),free thyroxine(FT4)in the study group were(3.10±1.36)mU/L,(5.76±1.25)pmol/L,(15.22±1.95)pmol/L,respectively,which were significantly lower than(4.88±1.47)mU/L,(7.13±1.32)pmol/L,(19.07±2.02)pmol/L in the control group(t=5.27,4.71,6.29,all P<0.05).Serum OCN,β-CTx,hS-CRP,and IL-6 in the study group were(17.36±2.62)μg/L,(0.32±0.04)μg/L,(4.07±0.86)mg/L,and(1.38±0.21)pg/L,respectively,which were significantly lower than(26.05±2.88)μg/L,(0.51±0.09)μg/L,(6.23±0.91)mg/L,(1.89±0.28)pg/L in the control group(t=12.37,10.40,7.39,8.57,all P<0.05).The incidence of adverse reactions in the study group was significantly lower than that in the control group[6.00%(3/50)vs.12.00%(3/50),χ^(2)=14.78,P<0.05).Conclusion Jikang Pingxiao prescription combined with methiimidazole can effectively reduce the inflammatory responses in patients with hyperthyroidism,inhibit the expression of OCN andβ-CTX in the serum,and improve thyroid function.The combined method is scientific and reasonable,and is suitable for clinical application.It has good therapeutic effects on hyperthyroidism and is worthy of clinical promotion.

关 键 词：甲状腺功能亢进症 甲状腺功能试验 中草药 甲巯咪唑 药物协同作用 骨钙素 C反应蛋白质 白细胞介素6 药物相关性副作用和不良反应 

分 类 号：R581.1[医药卫生—内分泌]